Bristol-Myers Squibb Company

- The company plans to take on additional debt in 2024 to finance the acquisitions of Karuna and RayzeBio. - Despite this new debt, the company has a strong financial position with $12.6 billion in cash and marketable securities. - The company generates strong cash flow, with $4.3 billion from operations in Q4 2023, and plans to repay approximately $10 billion of debt over the next two years to improve leverage. - No mention of new equity fundraising in the provided excerpts. - The approach reflects financial discipline to support business investments, acquisitions, and shareholder returns while managing leverage prudently.

- Business development remains a priority, focusing on strategic and financially sensible deals, including bolt-on opportunities, partnerships, and licensing. - Recent deals closed late last year require focus on integration; however, new deals are still being considered. - Planned acquisitions of Karuna and RayzeBio will be financed partly by taking on additional debt this year. - The company plans to repay approximately $10 billion of debt over the next two years to improve leverage. - Investments in growth portfolio execution and accelerating performance of new launches are ongoing, including expanding commercial footprint for products like Abecma. - Operating expenses expected to rise modestly due to these investments, alongside reallocation and efficiency initiatives. - Capital allocation balanced with maintaining strong operating margins, cash flow, and returning cash to shareholders through dividends and buybacks.

- 2024 revenue expected to increase in low single-digit range on an underlying basis, reflecting confidence in growth portfolio momentum. - Growth driven by increasing sales of Opdivo and recently launched products; Opdivo growth anticipated to be more modest than 2023 but may accelerate in second half of 2024 with new launches. - Strong growth expected from Eliquis in the U.S. throughout 2024. - Continued volume growth for Sotyktu anticipated, aiming to roughly double prescriptions to ~20,000 in Q4 2024 and maintain momentum into 2025. - Reblozyl sales forecasted to continue strong growth in 2024, supported by U.S. first-line MDS label and international launches. - Sales of Breyanzi expected to show strong growth starting in Q2 2024 with improved supply and new indications. - Camzyos volume momentum to continue in U.S. and modest international contribution anticipated. - Margin expected to evolve due to sales mix and higher rebates from improved access programs. - Total growth supported by new product launches, pipeline progress, and business development acquisitions.

- 2024 non-GAAP EPS guidance: $7.10 to $7.40. - Expected revenue growth: Low single-digit increase underlying, excluding currency impacts. - Gross margin projected at ~74%, reflecting sales mix changes and absence of prior year hedging gains. - Operating expenses (MS&A) to increase low single-digit range due to Mirati costs and efficiency reallocations. - Operating Income & Expense (OI&E) projected at ~$250 million income, including PD-1 royalty and Mirati financing costs. - Tax rate estimated around 17.5%, higher due to nonrecurrence items and Pillar 2 impact. - Earnings anticipated to be diluted by acquisitions: Karuna (~$0.30 EPS dilutive largely from financing costs), RayzeBio (~$0.13 EPS dilutive from financing and OPEX). - Company expects continued strong performance for key growth products like Eliquis, Opdivo, Reblozyl, and expansion through new launches. - Long-term targets reaffirmed; focus on accelerating pipeline and operational efficiency to drive sustainable growth toward late decade.

- Sotyktu is progressing well with ongoing efforts to build demand and secure access. - Normalized sales (excluding clinical trial orders) for Sotyktu increased about 40% versus Q3. - The base of paid prescriptions for Sotyktu is expected to roughly double by Q4 2024, targeting around 20,000 prescriptions. - Conversion from Bridge programs to commercial prescriptions is proceeding as planned, taking about 2-3 months per patient. - Negotiations with payers continue to secure more access, with recent one-step edits secured with ESI and Cigna, covering approximately 65 million lives combined. - Additional payer negotiations are ongoing to expand coverage further. - Clinical supply purchases contributed to some recent sales spikes (e.g., $17 million clinical supply purchase for Sotyktu in Q4). - For Reblozyl, ongoing strong demand with international launches and pending European approval expected in H1 2024. - Planning for significant growth in cell therapies (e.g., Breyanzi) is in progress, with expanded indications under priority review.